Metabolic, Mitochondrial & Redox Research Library

“Metabolic research” can refer to a mitochondrial-encoded peptide, a mitochondria-targeted analogue, a redox cofactor, an amino-acid derivative, a hormone-receptor agonist, an amylin analogue, a growth-hormone fragment, or a small-molecule chemical probe. Those materials do not become equivalent because studies measure energy expenditure, body mass, blood glucose, lipids, redox markers, or exercise-related endpoints.

This hub organizes research by identity and evidence model. It makes null results and development status visible: a favorable animal finding, an endogenous biomarker association, and a registered clinical trial answer different questions from a demonstrated human benefit.

This page is educational. It does not provide medical advice, treatment recommendations, dosing, preparation, administration, reconstitution, or directions for human or veterinary use. It does not authenticate a Serum Research catalog material or establish its quality, safety, or equivalence to a studied intervention.

Mitochondrial peptides and targeted analogues

MOTS-c

MOTS-c is a mitochondrial-derived peptide studied in biochemical, cell, and animal systems. The discovery paper reported metabolic findings in experimental models.[2] Later work combined mouse experiments with measurements of endogenous MOTS-c in humans after exercise; the human measurements were not a trial of externally supplied synthetic MOTS-c.[13]

At this source check, NCT07505745 was sponsor-reported as recruiting, with no posted results. Its last posted update was April 1, 2026.[22] Registration identifies a research proposal and reported status, not proof of favorable findings, actual conduct as described, FDA approval, or catalog identity. The trial-status checking guide explains these distinctions.

SS-31 / elamipretide

FDA’s substance record maps SS-31 and MTP-131 to elamipretide; the record itself does not confer approval.[24] Chemical form and lot-specific identity remain separate questions. In MMPOWER-3, a randomized trial in primary mitochondrial myopathy, neither the six-minute walk distance nor total fatigue co-primary endpoint was met at 24 weeks.[3] The MMPOWER-3 study record separates the primary findings, harms, missing data, and an abstract-versus-detailed-results discrepancy.

FDA granted accelerated approval to Forzinity in September 2025 to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. Approval relied on an intermediate clinical endpoint; continued approval may depend on confirmation of clinical benefit.[4,25] FDA’s ongoing accelerated-approval table continues to list the confirmatory requirement.[26] This is a different population and development program from MMPOWER-3. It is not approval for primary mitochondrial myopathy, a class-wide endorsement of “mitochondrial peptides,” or approval of a third-party SS-31 material.

For the earlier trials and their relationship to later evidence, read Elamipretide / SS-31: reading the MMPOWER trials, including crossover assumptions, exploratory secondary outcomes, and the distinction from the Barth syndrome indication.

Redox and metabolic cofactor research

NAD+ / nadide

NAD+ has a biochemical role in cellular metabolism, but that role alone does not establish an energy, DNA-repair, health, or longevity benefit from an external material. In one human pilot, the authors reported random allocation of eight men to NAD+ and three to a control group. They studied short-term plasma and urine metabolite changes, not clinical energy or longevity outcomes. The full paper discloses commercial research funding and clinic or consulting relationships; its small control group and short observation period limit the conclusions.[5]

FDA’s GSRS record identifies NADIDE as oxidized beta-NAD.[14] PubChem’s stereochemically specified beta-NAD record is CID 10897651.[15] NAD+, NADH, precursors, salts, hydrates, and finished formulations must remain distinct. A molecular formula or shorthand alone does not settle stereochemistry, protonation, formulation, or the basis of a reported amount.

L-carnitine / levocarnitine

FDA’s GSRS record identifies levocarnitine as the R stereoisomer and maps L-carnitine as a synonym.[16] The parent identity should not be conflated with D-carnitine, a racemate, acetyl-L-carnitine, propionyl-L-carnitine, or an unresolved salt or formulation.

A randomized cancer-fatigue trial enrolled 376 participants. Plasma carnitine increased, but the primary fatigue change at four weeks did not differ significantly from placebo.[6] That is a specific null clinical finding, not proof of equivalence or no possible effect in every setting. The negative and null results guide explains why a biochemical change and a patient outcome must be assessed separately.

Glutathione

Reduced and oxidized glutathione, salts, routes, and formulations require separate evidence. FDA’s June 2022 advisory-committee slide deck reviews proposed compounded glutathione uses. Its Parkinson’s-disease section describes a small intravenous controlled study and a follow-on intranasal phase 2b study whose assessed clinical outcomes did not show superiority to placebo. These specific null findings should not be generalized to every study listed in that presentation.[12]

That source is an official presentation about particular proposed uses, not a complete set of underlying trial reports, a generic “detoxification” finding, or a final regulatory determination. A biomarker result in one setting cannot establish clinical effectiveness for every glutathione form.

Incretin and amylin development research

Tirzepatide

Tirzepatide has named FDA-approved finished-product contexts. The available Zepbound S050 label, revised April 2026, describes weight-management and obstructive-sleep-apnea indications in specified adult populations.[7] The application history also lists an August 26, 2026 S041 supplement for which the corresponding label is not available on the site.[27] The April PDF should therefore not be treated as a complete account of every later labeling change.

The approved-drug versus research-material guide explains why a finished-product approval does not validate separately sold tirzepatide material, an unspecified formulation, or a receptor-class nickname.

Retatrutide

FDA’s substance record identifies retatrutide and maps LY3437943 and LY-3437943.[17] A primary development paper reports laboratory, mouse, and early human work,[18] and a later phase 2 obesity trial studied the defined molecule in a specified population.[19] The retatrutide phase 2 study record explains its estimand, analysis populations, nominal statistical comparisons, and adverse-event reporting.

At this source check, FDA identifies retatrutide as not a component of an FDA-approved drug.[8] Trial phase, completion, publication, and a UNII are not approval. “GLP-3” is not an adequate chemical specification and must not be used to infer catalog identity.

Cagrilintide

A phase 2 cagrilintide monotherapy trial provides development evidence in a defined population, not approval.[11] The published 32-week CagriSema phase 2 trial in type 2 diabetes randomized 92 participants to the combination, semaglutide alone, or cagrilintide alone. Those component arms support direct comparisons; it would be incorrect to say the study lacked them. The primary HbA1c comparison was the combination versus semaglutide and was not statistically significant. The HbA1c comparison versus cagrilintide was a secondary objective and favored the combination; weight was a supportive secondary outcome.[23,28]

The posted March 2022 analysis plan explicitly specifies no confirmatory hypothesis testing. These exploratory comparisons do not establish a general synergy claim, and the combination’s outcome must not be relabeled as cagrilintide monotherapy. The publication reports Novo Nordisk funding and gastrointestinal adverse events.[23,28] At this source check, FDA states that cagrilintide is not a component of an FDA-approved drug; FDA also states that retatrutide and cagrilintide cannot be used in compounding under federal law.[8]

Experimental metabolic compounds

AOD-9604

FDA’s briefing for the December 2024 advisory meeting distinguishes AOD-9604 free base and acetate and reviews their development for obesity. The assessment found insufficient effectiveness evidence; most of the reviewed human studies did not demonstrate benefit, including a large trial with a null primary weight outcome. Some reports lacked enough methodological detail for a full assessment.[9]

FDA staff concluded that the reviewed criteria weighed against section 503A-list inclusion. That advisory briefing is not a final determination or an approval. These human findings and reporting limits must remain visible alongside animal research.

5-Amino-1MQ

5-Amino-1MQ is a small molecule rather than a peptide. PubChem separately records the 5-amino-1-methylquinolinium cation, iodide, and chloride.[20] The cited experimental paper reports biochemical, cell, and mouse research; those experiments are not human clinical evidence.[21]

The shorthand does not complete the chemical specification or identify the counterion, and separate database entries do not prove which form a study or catalog lot contains. The free-base, salt, and counterion guide explains the wider form-versus-parent-identity distinction.

SLU-PP-332

SLU-PP-332 is an experimental estrogen-related receptor (ERR) agonist studied as a chemical probe in cell and mouse systems.[10] “Exercise mimetic” describes a preclinical research finding, not a demonstrated human performance, weight, metabolic, or treatment outcome.

Evidence patterns to watch

Pattern	What it supports	What it does not support
Endogenous level associated with a phenotype	An association in the measured tissue and population	Effect of an externally supplied material
Animal metabolic endpoint	A model-specific experimental result	Weight, performance, or disease outcomes in people
Biomarker change in a human study	Change in the named measurement	An unmeasured patient benefit
Combination trial with component comparators	Comparisons actually supported by its design and analysis	Automatic synergy or relabeling the combination outcome as monotherapy
Named FDA-approved product	Product- and application-specific status	Approval or equivalence of a research material
Registered or completed trial	A sponsor-reported research record and status	Positive results, approval, or catalog identity

NIH’s translational framework describes basic, preclinical, and clinical stages as informing one another, not a one-way progression.[1] The evidence-model guide explains why moving between those stages requires new evidence.

What this overview can and cannot establish

This is a source-guided overview, not a systematic review or a comprehensive comparison of efficacy or safety. Selected claims were checked against primary abstracts, accessible full papers, a posted analysis plan, identity databases, and official regulatory materials. Not every complete paper, protocol, appendix, or underlying dataset was available or independently reanalyzed. The AOD-9604 and glutathione sections rely on the cited FDA assessment or presentation, not a fresh analysis of every underlying trial.

Absence of a significant difference does not prove equivalence. A favorable estimate does not remove uncertainty, adverse effects, missing-data assumptions, or limits on generalization. None of these sources authenticates a Serum Research lot or supports a recommendation to use a catalog material.

Published compound records

Frequently asked questions

Does a mitochondrial mechanism prove a human metabolic benefit?

No. Mechanistic evidence can support a hypothesis in a defined system. Human outcomes require direct human evidence for an exact intervention, population, and protocol.

Does endogenous MOTS-c research show what synthetic MOTS-c does?

No. Measuring a naturally occurring peptide is not the same experiment as exposing participants to a manufactured material. A trial registration without results does not close that evidence gap.

Is every SS-31 material FDA approved because Forzinity is approved?

No. Approval is specific to the named finished product, application, manufacturing controls, population, and label. The Barth-syndrome approval does not establish a primary-mitochondrial-myopathy indication.

Can a favorable CagriSema study be described as cagrilintide monotherapy evidence?

Not by assigning the combination’s result to cagrilintide alone. The cited phase 2 study included both individual-drug comparators, which inform specific comparisons, but its analysis plan did not specify confirmatory hypothesis testing.

Does cellular NAD+ biology prove that external NAD+ improves energy or longevity?

No. A biochemical role is not an intervention outcome. The cited small human pilot measured metabolites, not those clinical benefits.

Does this hub rank compounds from strongest to weakest?

No. It organizes evidence by identity and research question. Evidence strength is specific to a claim and does not rate a catalog product.

Primary and official sources

Review and corrections

Sources checked September 2, 2026 (America/Edmonton), corresponding to September 3, 2026 (UTC). Regulatory and trial statuses can change after this check.

Serum Research is responsible for the editorial content and corrections. No independent scientific, clinical, statistical, analytical, or regulatory review is claimed. This page is nonmedical educational material and makes no catalog-quality or equivalence conclusion. See how we review evidence, browse the published study records or the research library, and contact us with a correction.

Are you over 21?

Metabolic, Mitochondrial, and Redox Research Library